Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
Ability Biologics Closes $18 Million Seed Funding Extension for Immunomodulators
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing